Revised EMA guideline on evaluating anticancer medicines to take effect on 1 July
This article was originally published in SRA
Executive Summary
The European Medicines Agency has finalised the revised version of its guideline on evaluating anticancer medicines, which deals with all stages of clinical development for drugs for treating malignancies1,2.
You may also be interested in...
New Evidence For Kisqali Secures Funding In England For Second-Line Use
The decision by health technology assessment body NICE on Novartis’s advanced breast cancer drug, Kisqali, contrasts sharply with its recommendation for another CDK4/6 inhibitor – Lilly’s Verzenios.
Dostarlimab, Zynteglo & COVID-19 Combo Drugs In The Spotlight At EMA
The sponsors of seven new drugs are set to find out this week whether the European Medicines Agency’s human medicines committee, the CHMP, will recommend pan-EU approval for their products. CHMP action is also expected regarding two potential combination therapies for COVID-19.
Lilly Undeterred By UK NICE Funding Blow For Second-Line Use Of Verzenios
Verzenios is one of three CDK4/6 inhibitors that are available via the Cancer Drugs Fund for use in previously treated patients with metastatic breast cancer, but it is the first for which health technology assessment body NICE has published a recommendation on routine commissioning.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: